Transdermal drug administration apparatus having microneedles

• US 8,419,708 B2
• Filed: 02/07/2007
• Issued: 04/16/2013
• Est. Priority Date: 02/10/2006
• Status: Active Grant

• Current Assignee: Hisamitsu Pharmaceutical Company Incorporated
• Original Assignee: Hisamitsu Pharmaceutical Company Incorporated
• Inventors: Tokumoto, Seiji, Matsudo, Toshiyuki, Kuwahara, Tetsuji
• Primary Examiner(s): Mehta, Bhisma
• Assistant Examiner(s): HAYMAN, IMANI N
• Application Number:
  US12/278,483
• Publication Number:
  US 20090030365A1
• Time in Patent Office: 2,260 Days
• Field of Search: 604/21, 604/22, 604/173, 604/272, 604/506, 604/27, 604/28, 604/70, 604/500, 427/2.3
• US Class Current: 604/506
• CPC Class Codes: A61M 2037/0007 having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
• CPC Class Codes: A61M 2037/0023 Drug applicators using microneedles
• CPC Class Codes: A61M 2037/003 having a lumen
• CPC Class Codes: A61M 2037/0046 Solid microneedles
• CPC Class Codes: A61M 37/0015 by using microneedles
• CPC Class Codes: A61N 1/306 Arrangements where at least part of the apparatus is introduced into the body

Abstract

It is intended to provide a transdermal drug administration apparatus having microneedles, which is capable of piercing the skin by a simple procedure in the transdermal administration of a biologically active substance (drug) and allows rapid absorption of the biologically active substance. The present apparatus comprises a microneedle device (50) comprising a microneedle substrate (53) having a plurality of microneedles (51) capable of piercing the skin, an absorbent (11) disposed thereon, the absorbent (11) comprising a material capable of absorbing a liquid, and a dissolving solution reservoir (18) disposed on the absorbent (11), the dissolving solution reservoir (18) containing a dissolving solution (16) for dissolving a drug and being capable of disrupting a diaphragm (20) provided the dissolving solution reservoir (18) and the absorbent (11) by pressing. A coating containing a dry drug is disposed on the microneedles (51) and/or the microneedle substrate (53).

Claims

1. A transdermal drug administration method, comprising:

putting, onto the skin, an apparatus comprising a microneedle device having a plurality of microneedles capable of piercing the skin and a microneedle substrate supporting the microneedles;

a coating disposed on the microneedles and/or the microneedle substrate, the coating containing a dry drug;

a pad portion disposed on the microneedle device; and

a dissolving solution reservoir disposed on the pad portion through a diaphragm, the dissolving solution reservoir containing a dissolving solution for drug dissolution and having a protruding portion formed therein, a tip of the protruding portion being linear or planar, the amount of the drug contained in the coating being 3-6 mg per 20 μ

L of the dissolving solution supplied to the microneedle substrate; and

by pressing the protruding portion of the dissolving solution reservoir to break the diaphragm, opening the dissolving solution reservoir to supply the dissolving solution to the pad portion and the microneedle device, and further piercing the skin with the microneedles, thereby allowing transdermal administration via the microneedles of the drug dissolved in the dissolving solution.

2. A transdermal drug administration method, comprising:

putting, onto the skin, an apparatus comprising a microneedle device comprising a plurality of microneedles capable of piercing the skin and a microneedle substrate supporting the microneedles;

a coating disposed on the microneedles and/or the microneedle substrate, the coating containing a dry drug; and

a dissolving solution reservoir disposed on the microneedle device through a diaphragm, the dissolving solution reservoir containing a dissolving solution for drug dissolution and having a protruding portion formed therein, a tip of the protruding portion being linear or planar, the amount of the drug contained in the coating being 3-6 mg per 20 μ

L of the dissolving solution supplied to the microneedle substrate; and

by pressing the protruding portion of the dissolving solution reservoir to break the diaphragm, opening the dissolving solution reservoir to supply the dissolving solution to the microneedle device, and further piercing the skin with the microneedles, thereby allowing transdermal administration via the microneedles of the drug dissolved in the dissolving solution.